Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study

David O Riordan,1 Carole Elodie Aubert,2 Kieran Walsh,1,3,4 Anette Van Dorland,2 Nicolas Rodondi,2,5 Robert S Du Puy,6 Rosalinde K E Poortvliet,6 Jacobijn Gussekloo,7 Carol Sinnott,8 Stephen Byrne,1 Rose Galvin,9 J Wouter Jukema,10 Simon P Mooijaart,11,12 Christine Baumgartner,2 Vera McCarthy,13 Elaine K Walsh,14 Tinh-Hai Collet,15 Olaf M Dekkers,16 Manuel R Blum,2 Patricia M Kearney4

ABSTRACT

Objectives To estimate and compare the prevalence and type of potentially inappropriate prescribing (PIP) and potential prescribing omissions (PPOs) among community-dwelling older adults (≥65 years) enrolled to a clinical trial in three European countries.

Design A secondary analysis of the Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial dataset.

Participants A subset of 48/80 PIP and 22/34 PPOs indicators from the Screening Tool of Older Persons Prescriptions/Screening Tool to Alert doctors to Right Treatment (STOPP/START) V2 criteria were applied to prescribed medication data for 532/737 trial participants in Ireland, Switzerland and the Netherlands.

Results The overall prevalence of PIP was lower in the Irish participants (8.7%) compared with the Swiss (16.7%) and Dutch (12.5%) participants (P=0.15) and was not statistically significant. The overall prevalence of PPOs was approximately one-quarter in the Swiss (25.3%) and Dutch (24%) participants and lower in the Irish (14%) participants (P=0.04) and the difference was statistically significant. The hypnotic Z-drugs were the most frequent PIP in Irish participants, (3.5%, n=4), while it was non-steroidal anti-inflammatory drug and oral anticoagulant combination, sulfonlureas with a long duration of action, and benzodiazepines (all 4.3%, n=7) in Swiss, and benzodiazepines (7.1%, n=18) in Dutch participants. The most frequent PPOs in Irish participants were vitamin D and calcium in osteoporosis (3.5%, n=4). In the Swiss and Dutch participants, they were bone antiresorptive/anabolic therapy in osteoporosis (9.9%, n=16, 8.6%, n=22) respectively. The odds of any PIP after adjusting for age, sex, multimorbidity and polypharmacy were (adjusted OR (aOR) 3.04 (95% CI 1.33 to 6.95, P<0.01) for Swiss participants and aOR 1.74 (95% CI 0.79 to 3.85, P=0.17) for Dutch participants compared with Irish participants. The odds of any PPOs were aOR 2.48 (95% CI 1.27 to 4.85, P<0.01) for Swiss participants and aOR 2.10 (95% CI 1.11 to 3.96, P=0.02) for Dutch participants compared with Irish participants.

Strengths and limitations of this study

► This is the first study to estimate and compare the prevalence and type of potentially inappropriate prescribing (PIP) and potential prescribing omissions (PPOs) using a subset of the Screening Tool of Older Persons Prescriptions/Screening Tool to Alert doctors to Right Treatment (STOPP/START) V2 criteria in community-dwelling older adults enrolled to a clinical trial across three different European countries.

► The Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial (TRUST) database contains comprehensive information on patient demographics, comorbidities and medication, and this facilitated the assessment and measurement of prescribing commission and omission for participants included in the clinical trial.

► The sample size (n=532) and sampling scheme may limit insights about prescribing nationally in the three countries.

► It was only possible to apply a subset of the criteria to the database due to a lack of information on drug strength, dose and duration of prescriptions, and this may explain the low prevalence of PIP and PPOs in the study.

► Some countries may have specific guidelines for the optimal treatment of conditions; therefore, these guidelines could differ from the recommendations in the STOPP/START criteria and could explain why some PIP and PPOs were identified in one population and not in others.

Conclusions This study has estimated and compared the prevalence and type of PIP and PPOs among this cohort of community-dwelling older people. It demonstrated a significant difference in the prevalence of PPOs between the three populations. Further research is urgently needed into the impact of system level factors as this has important implications for patient safety, healthcare provision and economic costs.
INTRODUCTION

Older people often have multiple comorbidities and as a consequence are frequently prescribed multiple drugs. This increases their risk of adverse drug events, extended hospital stays and mortality. Potentially inappropriate prescribing (PIP) describes any drug that has the potential to cause an adverse event which can outweigh its clinical benefit compared with alternative treatment options. Appropriateness of prescribing in older people can be assessed using either implicit (judgement-based) or explicit (criterion-based) screening tools. Implicit tools require healthcare professionals to assess the appropriateness of prescribing based on clinical guidelines and each patient situation. Explicit tools are usually developed from published literature, expert opinion and consensus techniques.

In recent years, the Screening Tool of Older Persons Prescriptions/Screening Tool to Alert doctors to Right Treatment (STOPP/START) criteria were developed and validated as an explicit measure of PIP and potential prescribing omissions (PPOs) for use in older adults (≥65 years) in European countries. All criteria are organised according to physiological systems for ease of use. In 2014, the STOPP/START criteria were revised and adapted to new evidence-based guidelines, STOPP/START version 2 (STOPP/START V2), comprising 80 STOPP and 34 START criteria. Several new STOPP categories created in V2 include antiplatelet/anti-coagulant drugs, drugs affecting, or affected by, renal function and drugs that increase anticholinergic burden. New START categories include urogenital system drugs, analgesics and vaccines. A number of criteria from V1 were removed in V2 due to a lack of evidence from the published literature.

A number of studies have reported the prevalence of PIP/PPOs in large populations of older adults using subsets of the STOPP/START V1 criteria. Cahir et al estimated the prevalence of PIP was 36% among adults ≥70 years in a primary care population in Ireland. In a similar study, Bradley et al reported a prevalence of PIP of 29% among older adults in primary care in the UK. Bruin-Huisman et al estimated the prevalence of potentially inappropriate medicines (PIMs) and PPOs among older patients in primary care in the Netherlands. In this retrospective longitudinal study, the mean prevalence of ≥1 PIMs and PPOs were 34.7% and 84.8%, respectively.

Urfer et al assessed the efficacy and safety of a prescriber checklist for reducing inappropriate prescribing among 900 patients ≥65 years admitted to an internal ward of a Swiss hospital. The study reported that 37% of patients had ≥1 PIM while 25% had ≥1 PPO. However, there is a lack of research exploring the prevalence of PIP and PPOs in community-dwelling older adults using the updated criteria. For example, Blanco-Reina et al reported a prevalence of PIP and PPOs of 40.4% and 21.8%, respectively, among older adults in Spain. In a study conducted in Turkey, 667 participants aged ≥65 years were admitted to an outpatient clinic of a university hospital. The prevalence of PIP reported was 39.1%. A study conducted among 319 older patients discharged from a hospital in Albania identified that 63% received at least one PIP.

In another study carried out in Ethiopia, the prevalence of inappropriate prescribing of antithrombotic therapy among 156 hospitalised elderly patients was assessed. The prevalence of PIP and PPOs were 51.4% and 48.6%, respectively. Therefore, the aim of this study is to estimate and compare the prevalence and type of PIP and PPOs among a sample of community-dwelling older adults enrolled to a clinical trial across three different European countries using a subset of the STOPP/START V2 criteria.

METHODS

Study population

This is a secondary analysis of the Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) Trial dataset. The full study protocol has been previously published, and a summary is provided here. The trial was conducted in four countries (Ireland, Scotland, Switzerland and the Netherlands). Community-dwelling participants aged ≥65 years with untreated subclinical hypothyroidism (SCH) were identified from clinical laboratory databases or by searching general practitioners’ (GPs’) databases/notes and were randomly assigned to levothyroxine or placebo. SCH was defined as persistently elevated thyroid stimulating hormone levels (4.6–19.9 mU/L) with free thyroxine (fT4) within the local laboratory reference range.

Medication information was available for three of the four countries (Ireland, Switzerland (one site, Bern) and the Netherlands). On enrolment to the study in Ireland and the Netherlands, participants self-reported their prescription medicines and medical history to the study nurses. In Ireland, this involved participants bringing their medicines or prescription and a list of their medical conditions to the study visit. In the Netherlands, the study visit was carried out in the participant’s home. In Switzerland, the study nurses received a list of the medical history and prescription medicines from the participant’s GP. When it was not possible to obtain either list, the participants self-reported their medical history and prescription medicines. If ambiguity occurred regarding the reporting of prescription medicines or medical history in any of the study sites, the participant’s GP or local pharmacy were contacted. The study nurses recorded all the participants’ prescribed medicines and entered them into an online electronic case report form (eCRF). Detailed information on participant demographics (date of birth, sex, race, smoking history, alcohol consumption), social circumstances (living arrangements, home support services, district nurse/public health nurse, informal caregiver), physical measurements (systolic and diastolic blood pressure, heart rate, weight, height, waist circumference) and medical history was also collected. The data for this study were obtained following access to the secure eCRF on the TRUST web portal.
Application of the STOPP/START criteria

There have been significant changes to the updated criteria. Firstly, there are more criteria in V2 (80 STOPP and 34 START compared with 65 STOPP and 22 START in V1). Secondly, new drug groups have been included in the updated criteria, for example, sulfonlureas with a long duration of action. Thirdly, a number of criteria from V1 were removed from V2 due to a lack of evidence from the published literature. Twelve STOPP V1 criteria were removed from V2. Twenty-seven new criteria were introduced in STOPP V2, and 22 of these were applied to the TRUST dataset. Three START V1 criteria were removed from V2, while 15 new criteria were introduced. Nine of these new criteria were applied to the TRUST dataset. The extra criteria included in V2 arose from new clinical trial information, new systematic review information and expert panel suggestions for new criteria. This highlights the need to update and revise the criteria on a regular basis as some criteria can become outdated or obsolete. Also, new drugs have entered the market since the V1 criteria were validated in 2008.

A subset of the STOPP/START V2 criteria were applied, as information required for some criteria (ie, drug strength, dose and duration of prescriptions) was not available in the TRUST dataset. There was consensus among the study pharmacists (DOR, KW and SB) on the number and type of criteria selected, based on the ability to confidently apply the criteria to the data available. Therefore, 48 PIP indicators and 22 PPOs indicators were applied (see online supplementary appendix 1). Prescription drugs identified from the database were used as proxies to indicate a diagnosis of certain clinical conditions such as Parkinson’s disease, glaucoma and gout. For example, if a participant was prescribed colchicine, this information was used as a proxy for a diagnosis for gout. This methodology has been used in previous studies. A coding scheme was then developed between DOR and KW. PIP and PPOs’ prevalence were estimated according to STOPP/START V2 and recorded in Microsoft Office Excel (2013). It was agreed a priori by the authors that DOR (research pharmacist) would manually apply the criteria to all the Irish, Swiss and Dutch data. For validation purposes, the criteria were applied independently by a second member of the research team. KW (research pharmacist) applied the criteria to a random 10% sample of the Irish and Dutch data. CEA (research medical doctor) applied the criteria to a random 10% sample of the Swiss data. There are two studies (OPERAM, SENATOR) currently assessing the automatisation of the STOPP/START criteria to identify PIP and PPOs in older people. The results from both studies should inform on the best method of automatising screening tools to identify PIP and PPOs in this group of people. Therefore, the method used in this study for assessing the STOPP/START criteria should be considered as valid.

Outcomes

The main outcome of interest was the overall prevalence of any PIP or PPOs within participants from the TRUST trial in Ireland, Switzerland and the Netherlands according to a subset of the STOPP/START V2 criteria. Secondary outcome measures were (1) the prevalence of PIP and PPOs for each individual STOPP/START V2 criterion; (2) the most common PIP and PPOs in each country and (3) the association between the explanatory variables country, age, sex, multimorbidity and polypharmacy and dependent variables PIP and PPOs.

Statistical analysis

Data analyses were performed using StataV.13 (StataCorp, College Station, Texas, USA). Statistical significance was considered P<0.05. Characteristics of included participants were stratified by country. Continuous variables were presented as mean with SD and range, or median with IQR, as appropriate, and categorical variables as frequency (percentage). The overall prevalence of PIP/PPOs was defined as the proportion of participants having at least one PIP or PPO according to the STOPP/START V2 criteria among all participants included in this analysis and was further stratified by country. The prevalence estimates were compared using the χ² test. Participants were further classified by sex and age group (65–74 years, ≥ 75 years). Other explanatory variables included polypharmacy, defined as the concurrent use of five or more medications, and multimorbidity (co-occurrence of three or more chronic conditions). The association between age, sex, multimorbidity, polypharmacy and country with any PIP/PPOs (vs none) was assessed using multivariable logistic regression and presented as adjusted OR (aOR) with 95% CI and P values. Multicollinearity between the independent variables polypharmacy and multimorbidity was assessed by calculating the variance inflation factor (VIF). Sensitivity analysis excluding criteria triggered by combination of more than one drug was also performed.

Standardised reporting guidelines

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) standardised reporting guidelines for cross-sectional studies have been followed to ensure the uniform conduct and reporting of the research (see online supplementary appendix 2).

RESULTS

Population characteristics

The population characteristics of the 532 out of 737 included TRUST participants are detailed in table 1. The mean age (±SD) of participants were 74.6 (5.9) in Ireland, 76.4 (5.9) in Switzerland and 76.1 (6.8) years in the Netherlands. The proportion of women varied across countries from 42.6% in Ireland and 46.3% in Switzerland to 65% in the Netherlands. Hypertension (which was defined from participants’ medical history) was the most common morbidity reported in each country (Ireland...
The overall prevalence of PIP in the three populations was 12.9% (n=69). It was lower in the Irish participants (8.7%, n=10) compared with the Swiss (16.7%, n=27) and Dutch (12.5%, n=32) participants (P=0.15). In Ireland, 7% (n=8) of participants had a single PIP compared with 13.6% (n=22) of participants in Switzerland and 11.8% (n=30) of participants in the Netherlands. In Ireland, 1.8% (n=2) of participants had two or more PIP compared with 3.1% (n=5) of participants in Switzerland and 0.8% (n=2) of participants in the Netherlands.

The overall prevalence of PPOs in the three populations was 22.2% (n=118). It was approximately one-quarter in the Swiss (25.3%, n=41) and Dutch (24%, n=61) participants and lower in the Irish (14%, n=16) participants (P=0.04). In Ireland, 12.0% (n=14) of participants presented with one PPO compared with 15.4% (n=25) of participants in Switzerland and 13.7% (n=35) of participants in the Netherlands. In Ireland, 1.7% (n=2) of participants presented with two or more PPOs compared with 9.9% (n=16) of participants in Switzerland and 10.2% (n=26) of participants in the Netherlands.

The overall prevalence of PIP and PPOs in each country

The prevalence of the most common comorbidities in each country are also provided (see online supplementary appendix 3). The median number of drugs (IQR) prescribed to participants in each country was 4 (2–6).

Overall prevalence of PIP and PPOs in each country

The most common PIPs in each country

The most common PPOs in each country

Table 1  Baseline characteristics

<table>
<thead>
<tr>
<th>Population characteristics (n=532)</th>
<th>Ireland</th>
<th>Switzerland</th>
<th>Netherlands</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, n (% of total population in study)</td>
<td>115 (21.6)</td>
<td>162 (30.5)</td>
<td>255 (47.9)</td>
<td></td>
</tr>
<tr>
<td>Mean age (years) (±SD), range</td>
<td>74.6 (5.9), 66–95</td>
<td>76.4 (5.9), 66–92</td>
<td>76.1 (6.8), 66–95</td>
<td>0.054</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>49 (42.6)</td>
<td>75 (46.3)</td>
<td>166 (65.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>5 (4.3)</td>
<td>12 (7.4)</td>
<td>24 (9.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Mean alcohol consumption (units per week) (±SD)</td>
<td>5.5 (9.4)</td>
<td>3.6 (4.9)</td>
<td>7.4 (10.3)</td>
<td>0.008</td>
</tr>
<tr>
<td>Living arrangements (co-habiting), n (%)</td>
<td>77 (66.9)</td>
<td>91 (56.2)</td>
<td>161 (63.1)</td>
<td>0.021</td>
</tr>
<tr>
<td>Mean body mass index (±SD)</td>
<td>28.3 (4.3)</td>
<td>27.5 (4.9)</td>
<td>27.8 (4.8)</td>
<td>0.318</td>
</tr>
<tr>
<td>Most common morbidity, hypertension, n (%)</td>
<td>75 (65.2)</td>
<td>83 (51.2)</td>
<td>114 (44.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>Median number of drugs prescribed per patient, IQR</td>
<td>4 (2,5)</td>
<td>4 (2,5)</td>
<td>4 (2,6)</td>
<td>0.828</td>
</tr>
<tr>
<td>Polypharmacy, n (%)</td>
<td>51 (44.3)</td>
<td>60 (37.0)</td>
<td>106 (41.6)</td>
<td>0.447</td>
</tr>
<tr>
<td>Mean (±SD) EuroQol 5D: EQ Visual Analogue Scale score/100</td>
<td>82 (15.2)</td>
<td>82 (12.1)</td>
<td>76 (11.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean (±SD) Mini-Mental State Examination (/30)</td>
<td>28 (2.2)</td>
<td>28 (1.8)</td>
<td>29 (1.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mean (± SD) †TRUST Barthel Index/22</td>
<td>22 (1.0)</td>
<td>22 (1.0)</td>
<td>22 (1.0)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

*Living arrangements: whether participants were co-habiting or living alone.
†Polypharmacy: defined as five or more regular medicines.
‡An extra question was added under the heading ‘Bladder’: ‘does the participant have a urinary catheter?’

TRUST, Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial.
prescribing omissions of vitamin D and calcium supplement in participants with known osteoporosis and/or previous fragility fracture(s) (6.3%, n=16).

**Factors associated with PIP**

Table 2 shows the univariable and multivariable logistic regression analysis for the association between age, sex, multimorbidity and polypharmacy with PIP. In the univariable and multivariable models, there was no statistically significant association between age or sex and PIP. However, the association between multimorbidity or polypharmacy and PIP was statistically significant for both models.

Further analysis demonstrated that the odds of any PIP after adjusting for age, sex, multimorbidity and polypharmacy were aOR 3.04 (95% CI 1.33 to 6.95, P<0.01) for Swiss participants and aOR 1.74 (95% CI 0.79 to 3.85, P=0.17) for Dutch participants compared with Irish participants.

**Factors associated with PPOs**

Table 3 shows the univariable and multivariable logistic regression analysis for the association between age, sex, multimorbidity and polypharmacy with PPOs. In the univariable model, the association between age or multimorbidity and PPOs was statistically significant. However, the association was not statistically significant for polypharmacy.

The odds of any PPOs after adjusting for age, sex, multimorbidity and polypharmacy were aOR 2.48 (95% CI 1.27 to 4.85, P<0.01) for Swiss participants and aOR 2.10 (95% CI 1.11 to 3.96, P=0.02) for Dutch participants compared with Irish participants.

The VIF for multimorbidity and polypharmacy were 1.82 and 2.13, respectively. Sensitivity analysis excluding criteria triggered by combination of more than one drug had no effect on the study results.

**DISCUSSION**

**Results in the context of the current literature**

A systematic review of 13 research studies described the application of the STOPP/START V1 criteria in different healthcare settings. The prevalence of PIP and PPOs ranged from 21% to 79% and 23% to 74%, respectively. Studies reporting the prevalence of PIP and PPOs using the expanded STOPP/START V2 criteria in large populations of older people are limited. The overall prevalence of PIP and PPOs in our study was lower compared with previous studies carried out in Spain, Turkey, Albania and Ethiopia. However, this may have been due to differences in number and type of criteria applied to the data and the population studied.
In this study, the prescribing of benzodiazepines was identified as a common PIP among Dutch (7.1%, n=18) and Swiss participants (4.32%, n=7). However, in Ireland, it was reported at <1% (n=1). These findings are in keeping with a recent panel survey in Ireland using patient-level dispensing data, highlighting that benzodiazepines were one of the few medicines without a yearly increase in prescribing between 1997 and 2012.25 In 2009 a nationwide programme was introduced in the Netherlands which aimed to reduce the prescribing rates of benzodiazepines. Dutch GPs are required to state the indication for all benzodiazepines prescribed to allow patients apply for reimbursement of the medicine costs.26 In Switzerland, no similar programme exists. In Ireland, GPs receive a printout of their benzodiazepine prescribing from the General Medical Scheme (GMS). The GMS is a national tax-funded health insurance programme that provides access to medical and surgical services for low-income individuals/families and older people.27 This feedback highlights the prescribing practice of the GPs compared with their peers and allows them to carry out a clinical audit in this topic area. The audit also provides GPs with the necessary tools to identify best practice, and this may have impacted on the low prescribing of benzodiazepines in the study compared with the two other countries. This low prevalence could also be due to a difference in the sampling approach in Ireland or it may have occurred by chance.

Frequent PPOs across all three populations included vitamin D and calcium supplements in participants with...
known osteoporosis and/or fractures. These findings are similar to a previous study that used STOPP/START VI criteria in a primary care setting in Ireland.\(^{28}\) Prescribing of proton pump inhibitors (PPIs) at full therapeutic dose for >8 weeks is one of the most common STOPP criteria reported in studies but was not reported in this study as information relating to drug duration was not available.\(^{9,25}\)

The screening process and identification of potential participants for this clinical trial differed between countries and may explain some of the differences in the prevalence of PIP and PPOs. In Ireland, clinical trial nurses visited individual GP surgeries and with GP approval performed a search of the GPs’ databases/notes to identify potentially eligible participants. The GP then confirmed whether the participant was eligible to participate in a screening visit. In Switzerland and the Netherlands, potential participants were identified directly from clinical laboratory databases. A list of potential participants was sent to their GPs to confirm their eligibility in the trial. This screening process was carried out twice by the GPs and those who were deemed eligible were invited to participate.\(^{16}\) This process may have introduced selection bias at GP level as only GPs interested in participating in a clinical trial facilitated recruitment and also at the patient level as GPs may have excluded more complex patients.

Furthermore, in Ireland and the Netherlands, GPs play a gatekeeping role, that is, referral to specialist services in general comes from GPs.\(^{29,30}\) Whereas in Switzerland, participants can visit medical specialists directly if necessary.\(^{30}\) A systematic review and meta-ethnographic synthesis of GPs’ experiences on the clinical management of multimorbidity identified ‘Disorganisation and fragmentation of healthcare’ as a key difficulty. The authors highlighted that GPs have a more holistic view of the patient in contrast to specialists who manage disease-specific conditions.\(^{31}\) As Swiss patients can visit medical specialists directly if necessary, they may receive more non-essential medicines. The prescribing process is further complicated if patients attend several specialists. Also, if there is a lack of collaborative decision-making between the patients’ GP and medical specialists this could result in a higher prevalence of PIP/PPOs among Swiss participants. Therefore, enhancing collaborative decision-making between GPs and specialists may help to optimise the prescribing of older patients. Finally, some countries may have specific guidelines for the optimal treatment of conditions. These guidelines could differ from the recommendations in the STOPP/START criteria and could explain why some PIP and PPOs were identified in one population and not in others.

### Clinical and policy implications

Our findings indicate that the overall prevalence of PIP using a subset of the STOPP/START V2 criteria across three European populations was 12.9%. As PIP is associated with adverse health outcomes, healthcare providers should aim to reduce their prevalence.\(^{32,33}\) A recent systematic review of 12 randomised controlled trials concluded that various interventions including pharmacist interventions, clinical decision support systems and multifaceted approaches can reduce inappropriate prescribing.\(^{34}\) However, it was unclear whether these interventions led to clinically significant improvements in patient outcomes due to the variability in methodological quality of the included studies and the heterogeneity of the interventions and outcomes measured.\(^{34}\) Further large randomised controlled trials that are methodologically robust, adhere to the appropriate reporting guidelines and have a long duration of follow-up are needed to address the efficiency of such interventions to reduce the prevalence of PIP/PPOs and improve patient outcomes.

The potential role for medication reviews incorporating explicit screening tools of PIP for participants recruited to clinical trials requires further investigation. This may provide trials with important information on the complex nature of prescribing medication regimens in such participants, and how new interventions are expected to perform alongside these regimens. In addition, the cost of conducting these interventions in clinical trial participants should also be explored. Finally, screening tools such as the STOPP/START criteria have proven to be very beneficial not only in identifying the prevalence of PIP/PPOs in studies but also in intervention studies to improve medication appropriateness and reduce the risk of adverse drug reactions (ADRs) in older people.\(^{35}\) The updated version with the additional criteria will help to identify a larger number of PIP and PPO

---

<table>
<thead>
<tr>
<th>Explanatory variable</th>
<th>Univariable model</th>
<th>Multivariable model*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.04 (1.01 to 1.08)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females (vs males)</td>
<td>1.41 (0.93 to 2.14)</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multimorbidity†</td>
<td>3.04 (1.99 to 4.65)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polypharmacy‡</td>
<td>1.30 (0.86 to 1.96)</td>
<td>0.21</td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, multimorbidity, polypharmacy and country.
†Multimorbidity: defined as the co-occurrence of three or more chronic conditions.
‡Polypharmacy: defined as five or more regular medicines.
instances and therefore has a greater potential to reduce ADRs and improve other relevant patient outcomes.

**Strengths and limitations of the study**

To the best of our knowledge, this is the first study to estimate and compare the prevalence and type of PIP and PPOs using a subset of the STOPP/START V2 criteria in community-dwelling older adults across different European populations. It also offered an opportunity to compare the characteristics of trial participants recruited by sites in different countries, and to compare prescribing behaviours internationally. International comparisons can support or refute arguments for change in healthcare, serve as an additional lens on the state of the quality of care provided nationally and can help build the evidence base necessary to identify problems and understand changes in the quality of care between countries.

The TRUST database contains comprehensive information on patient demographics, comorbidities and medication. This facilitated the assessment and measurement of prescribing commission and omission for participants randomised to the clinical trial. A number of different approaches for optimising prescribing appropriateness have been published. For example, comprehensive geriatric assessment is a time-consuming and resource-intensive strategy to deploy and is more commonly used for intervention rather than prevalence studies. Therefore, STOPP/START was considered the most appropriate and feasible tool for this study. The STOPP/START V2 criteria were applied by a pharmacist (DOR) who is familiar with using this screening tool. To enhance the validity of the results, a sample of the data was independently reviewed by two healthcare professionals. It was agreed *a priori* to perform the multivariable analysis at the level of the patient rather than individual drug as the aim of the study was to estimate and compare the prevalence and type of PIP and PPOs in the study population.

It is acknowledged that the sample size (n=532) is relatively small; however, the aim was to estimate and compare the prevalence and type of PIP and PPOs in a sample of patients from three different European countries. The study population was based on participants enrolled to a clinical trial and may be somewhat different from the general population. However, the main inclusion criteria for the TRUST trial are quite broad. Second, although the data are based on a population of patients with SCH, there is no evidence to suggest that this would influence their chance of having a PIP or PPO. Although different approaches to the collection of medication data were used in each country, the authors (and the TRUST consortium with regards to safety) believe that all methods are thorough enough to capture all medications. For example, studies have highlighted that self-report medications are most likely to be congruent with patient records as a measure of current medications. Although prescription drugs were used as proxies to indicate diagnoses, the possibility that these drugs may have been used to treat other conditions cannot be excluded. It was only possible to apply a subset of the STOPP/START V2 criteria as information required for some criteria (ie, drug strength, dose and duration of prescriptions) was not available in the TRUST dataset. For example, the prescribing of PPs at full therapeutic dose for >8 weeks was not reported. This may have contributed to an underestimation of the real prevalence of PIP in the study. Also, some of the criteria could be more explicit. For example, the C1 STOPP criterion ‘long-term aspirin at doses greater than 160 mg per day’ does not define ‘long term’. This requires further clarification in future versions of the criteria. Although Swiss patients can avail of a healthcare plan that requires them to visit the GPs first, the GP may not have comprehensive information on all the patients’ medicines. This includes information on over-the-counter medicines such as aspirin and NSAIDs which are included in the STOPP criteria and may explain the difference in PIP prevalence in these patients. Finally, the TRUST trial concerned patients with SCH. It is possible that women with SCH were more likely than men to have been treated by doctors and therefore not eligible for the trial as doctors tend to associate thyroid disease more with women. Also, SCH symptoms can overlap with postmenopausal symptoms that women report (ie, tiredness, low mood), therefore pushing doctors to treat this condition.

**CONCLUSIONS**

These study findings highlight that PIP and PPOs are prevalent among a sample of community-dwelling older people enrolled to a clinical trial in three European countries. The screening process and identification of potential patients for this clinical trial differed between the countries and may explain some variation in the populations recruited and prevalence of PIP and PPOs. This study is an important first step to justify the need for large comparative studies using routine data. This can then help to inform policy or the development of appropriate interventions on optimising prescribing practices in older adults at a national or international level. Further research is urgently needed into the impact of syste-level factors as this has important implications for patient safety, healthcare provision and economic costs.

**Author affiliations**

1Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Republic of Ireland
2Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3Centre for Gerontology and Rehabilitation, School of Medicine, University College Cork, Cork, Republic of Ireland
4School of Public Health, University College Cork, Cork, Republic of Ireland
5Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
6Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
7Department of Public Health and Primary Care and Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
8THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge, Cambridge, United Kingdom
9Department of Clinical Therapies, Health Research Institute, University of Limerick, Limerick, Republic of Ireland


Stott DJ, Gussakello J, Kearney PM, et al. Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). BMC Endocr Disord 2017;17:6.


